MARKHAM, ON, April 16, 2018 /CNW/ - MedReleaf Corp. (TSX:LEAF) ("MedReleaf" or the "Company"), Canada's first and only ISO 9001 and ICH-GMP certified cannabis producer, today announced the introduction of Product Identification Numbers, or "PINs", for 57 of its unique medical cannabis products including dried flower, oils and capsules. With this announcement, MedReleaf continues to demonstrate leadership among Canadian licensed producers to facilitate the coverage of medical cannabis on employer-sponsored benefits plans.

Product Identification Numbers (PINs) are similar to traditional Drug Identification Numbers (DINs), designed to make it easier for employers and payers to classify and incorporate pharmaceutical and health care products into benefits coverage plans.

"Medical cannabis is being covered by an ever-increasing number of employers across Canada through health spending accounts and extended health benefits plans, but without an identification number for each product, it can be difficult to incorporate and track the use of our products within core health benefits programs," said Robert, Gora, Senior Director of Physician Outreach. "Introducing PINs will help willing insurers and employers to list MedReleaf's cannabis medicines on their formularies, improving access and cannabis drug coverage for patients across Canada."

"We have extensive experience in developing programs to support large patient groups and we are encouraged by the growing interest we are seeing from employers and payers in covering medical cannabis products," noted Neil Closner, CEO of MedReleaf. "Working with employers to update workplace drug and alcohol policies, providing guidance on benefit plan design, and now adding PINs to our industry-leading products, are all proof points of our commitment to leadership, innovation and education regarding the therapeutic benefits of cannabis."

About MedReleaf Corp.

Voted Top Licensed Producer at the 2017 Lift Canadian Cannabis Awards, MedReleaf is an R&D-driven company dedicated to innovation, operational excellence and the production of top-quality cannabis. Sourced from around the world and carefully cultivated in one of two state of the art ICH-GMP and ISO 90001 certified facilities in Ontario, the Company delivers a variety of premium products for the global medical market and is committed to serving the therapeutic needs of its medical patients and providing a compelling product assortment for the adult-use recreational consumer.

For more information on MedReleaf, its products, research and how the company is helping patients #livefree, please visit MedReleaf.com or follow @medreleaf

SOURCE MedReleaf Corp.

For further information: Dennis Fong, Investor Relations, [email protected], 416-283-9930

Related Links

www.medreleaf.com

